Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 185

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 4
Chunk 185
---
; (v) Series C Warrants
to purchase 81,753 shares of Common Stock at an exercise price of $0.04; (vi) December 2024 and January 2025 Common Warrants to purchase
an aggregate of 247,914 shares of Common Stock at an exercise price ranging from $5.61 to $5.82, (vii) February 2025 Common Warrants to
purchase an aggregate of 2,551,020 shares of Common Stock at an exercise price of $1.96, (viii) Pre-Funded Warrants to purchase an aggregate
of 215,740 shares of Common Stock at an exercise price of $0.0001, (ix) Public Warrants and Private Placement Warrants to purchase an
aggregate of 91,925 shares of Common Stock at an exercise price of $1,150.00 per share and (x) 6,250 shares of Series D Preferred Stock
with a conversion value of approximately $5 million, convertible into shares of Common Stock at a conversion rate of the stated value
thereof divided by a current effective conversion price of $0.78.

Although each of the conversion price of most
of the Preferred Shares and the exercise prices of the December 2024 Common Warrants, January 2025 Common Warrants, Series A Warrants
and February 2025 Common Warrants are at or above the trading price of our Common Stock as of the date of this Quarterly Report, if such
trading price increases, such conversion prices and exercise prices will not change as a result thereof and could be below the trading
price of our Common Stock as of the date of any future conversion or exercise thereof, resulting in dilution to our stockholders. In addition,
the terms of the Series A Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock and Series D Preferred Stock contain
certain penalties and adjustments to the amount included in determination of the conversion rate following certain breaches of the Company’s
obligations thereunder, including, among other things, as a result of a failure to file or cause the SEC to declare one or more registration
statements relating to the resale of the shares of Common Stock issuable upon conversion thereof by specified deadlines, certain defaults
under indebtedness of the Company or judgments against the Company and failure to deliver shares of Common Stock upon conversion in a
timely manner. For example, the penalties and adjustments include a 25% premium added to the stated